Shenzhen Hepalink Pharmaceutical Group Co., Ltd. engages in the manufacture and sale of pharmaceutical products in Hong Kong, the United States, Europe, Mainland China, and internationally. It operates through four segments: Finished Dose Pharmaceutical Products, Active Pharmaceutical Ingredients (API), Contract Development and Manufacturing Organization, and Others. The company's pharmaceutical products consist of finished dose pharmaceutical products, which primarily include enoxaparin sodium injection; API products, including heparin sodium API and enoxaparin sodium API; and other products, such as pancreatin API. It is also involved in the provision of research and development, manufacturing, quality management, and program management services. In addition, the company engages in research, development, production, services, and trading biopharmaceutical; property management, investment management and consulting, biopharmaceutical technology development and consulting, and equity and venture investment activities; production and sale of heparin sodium; provision of services on pharmaceutical related activities; and trading of medical and biopharmaceutical products. The company was formerly known as Shenzhen Hepalink Pharmaceutical Co.,Ltd. and changed its name to Shenzhen Hepalink Pharmaceutical Group Co., Ltd. in February 2017. Shenzhen Hepalink Pharmaceutical Group Co., Ltd. was founded in 1998 and is headquartered in Shenzhen, the People's Republic of China.